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Abstract
Aims To assess treatment satisfaction and weight-related quality of life (QOL) in subjects with Type 2 diabetes treated with
exenatide once weekly (QW) or twice daily (BID).
Methods In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and⁄or
oral glucose-lowering medications received either exenatide QW or BID during weeks 1–30; thereafter, subjects receiving
exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30–52. Diabetes
Treatment Satisfaction Questionnaire—status (DTSQ-s) and Impact of Weight on Quality of Life—Lite (IWQOL-Lite) were
assessed at baseline and weeks 30 and 52. Mean group changes from baseline to week 30 were estimated by ancova; changes
from week 30 to week 52 were assessed by Student’s t-test.
Results Statistically signiﬁcant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s
and IWQOL-Lite measures, with signiﬁcantly greater reduction in perceived frequency of hyperglycaemia and greater
satisfaction with continuing treatment in the QW group compared with the BID group. Effect sizes for change in DTSQ-s total
scoreswere0.84QW,0.64BID;forIWQOL-Lite:0.96QW,0.82BID.TreatmentsatisfactionandQOLimprovedsigniﬁcantly
between weeks 30 and 52 for those switching from BID to QW. Occurrence of adverse events did not affect patients’
improvements in treatment satisfaction and QOL.
Conclusions Patients treated with exenatide QW or BID experienced signiﬁcant and clinically meaningful improvements in
treatment satisfaction and QOL. Patients who switched from exenatide BID to exenatide QW administration reported further
signiﬁcant improvements.
Diabet. Med. 26, 722–728 (2009)
Keywords exenatide, treatment satisfaction, Type 2 diabetes mellitus
Abbreviations AE, adverse event; BID, twice daily; DTSQ, Diabetes Treatment Satisfaction Questionnaire; HbA1c,
glycated haemoglobin; IWQOL-Lite, Impact of Weight on Quality of Life—Lite; LS, least squares; PRO, patient-reported
outcome; QOL, quality of life; QW, once weekly; sd, standard deviation; TEAE, treatment-emergent adverse event
Introduction
The incidence of Type 2 diabetes is increasing [1]. Over 80% of
allpeoplewithType2diabetesareoverweightandover50%are
obese [2]. For patients with diabetes, obesity exacerbates
metabolic problems, leading to increased morbidity and
mortality [3]. Both Type 2 diabetes [4] and obesity [5] are
associated with diminished health-related quality of life (QOL).
Unfortunately, some effective glucose-lowering therapies may
not only contribute to weight gain [6], but they may also lower
treatment satisfaction and QOL [7–9].
Exenatide is a ﬁrst-in-class glucagon-like peptide 1 receptor
agonistapprovedforthetreatmentofType2diabetes.Exenatide
improves glycaemic and clinical parameters that could affect
treatment satisfaction and QOL, including improved blood
glucose control, decreased appetite and reduced weight [10,11].
Signiﬁcant beneﬁts have been seen in patients taking exenatide
twice daily (BID) and in those taking an exenatide once weekly
(QW) formulation [10–12].
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BID and QW treatment on treatment satisfaction and QOL of
patients with Type 2 diabetes managed with diet and exercise
and⁄or oral glucose-lowering medications [13,14]. Treatment
satisfactiondeservesattentionbecauseitmayinﬂuencetreatment
adherence [15] and consequent clinical outcomes [15–17].
Quality of life is a critical outcome in its own right and a
growing number of clinical trials now incorporate measures of
health-related QOL as primary or secondary outcomes. We
chose to use disease-speciﬁc measures for treatment satisfaction
and QOL in the current study because such measures are
generally considered more sensitive than generic measures to the
predicted effects of clinical trial interventions [18].
In this study we attempted to answer the following questions:
(i)doesexenatidetreatmentaffectdiabetestreatmentsatisfaction
and are changes in treatment satisfaction different for patients
taking exenatide QW and BID?; (ii) does exenatide treatment
affect weight-related QOL and are changes in weight-related
QOL different for patients taking exenatide QW and BID?; (iii)
do patients who switch from exenatide BID to exenatide QW
experience further improvement in treatment satisfaction and
QOL. In addition, we also assessed whether there are any
differences in treatment satisfaction and weight-related QOL in
those patients who did or did not report certain adverse events
(AEs).
Research design and methods
Data source
Data for this study were obtained from a randomized, multi-
centre, open-label study of subjects with Type 2 diabetes
managed with diet and exercise and⁄or oral glucose-lowering
medications. Two hundred and ninety-ﬁve patients received
exenatide either once weekly (2 mg, QW) or twice daily (10 lg,
BID) during weeks1–30. The primary endpoint of the study was
changeinglycatedhaemoglobin(HbA1c)at30weeks.Following
30 weeks,258patientscontinuedontoanopen-endedtreatment
periodwithexenatideQW.Resultsofthisstudyto30 weeksand
to 52 weeks for HbA1c, fasting plasma glucose, weight and
adverse events are reported elsewhere [13,14]. Brieﬂy, the
exenatide QW group showed greater improvements in HbA1c
()1.9vs.)1.5%forexenatideBIDat30 weeks;P = 0.0023)and
fastingplasmaglucose()2.3vs.)1.4 mmol⁄lforexenatideBID;
P < 0.0001), with similar levels of weight loss and adverse
events. There was no major hypoglycaemia in either exenatide
regimen. One patient who received exenatide QW with non-
sulphonylurea background therapy had an episode of minor
hypoglycaemia.Mostminorhypoglycaemiaoccurredinpatients
usingconcomitantsulphonylurea(eightof55receivingexenatide
QW and eight of 54 receiving exenatide BID).
The presence of an AE of nausea or vomiting was deﬁned as
having at least one treatment-emergent adverse event (TEAE)
during the 30-week treatment period; two subjects in each
treatment arm withdrew from the study as a result of nausea or
vomiting. The presence of injection site reactions was deﬁned as
havingatleastoneTEAEduringthe30-weekcomparisonperiod
with Medical Dictionary for Regulatory Activities (MedDRA)
preferred terms comprising any of the following ‘injection site’
terms: bruising, erythema, haematoma, haemorrhage,
induration, irritation, nodule, pain, pruritus, rash, swelling or
urticaria.
Patient-reported outcome (PRO) instruments
Patients completed a measure of diabetes treatment satisfaction,
theDiabetesTreatmentSatisfactionQuestionnairestatusversion
(DTSQ-s) and a measure of QOL, the Impact of Weight on
Quality of Life—Lite (IWQOL-Lite), at baseline and weeks 30
and 52. Patients were asked to complete the PRO instruments at
thebeginningoftheirclinicvisit,priortoanyprocedures.Patients
who terminated their participation prior to week 30 were asked
to complete the study questionnaires as part of their early
termination assessment.
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Diabetes treatment satisfaction was assessed with the Diabetes
Treatment Satisfaction Questionnaire—status version (DTSQ-s)
[19].
The DTSQ-s contains eight items assessing: overall treatment
satisfaction, treatment convenience and ﬂexibility, satisfaction
with understanding of diabetes, willingness to continue present
treatment and to recommend it to others and frequency of
unacceptably high and unacceptably low blood glucose levels.
Response categories for all items are on a 7-point Likert scale.
DTSQ-s scores range from 0 (e.g. very dissatisﬁed) to 6 (e.g. very
satisﬁed). All items except perceived hypoglycaemia and
hyperglycaemia items are summed to produce a total treatment
satisfaction score. The DTSQ-s total treatment satisfaction
scores range from 0 to 36. Higher scores on the DTSQ-s total
score indicate higher satisfaction. The perceived frequency of
hyperglycaemia and hypoglycaemia items are scored separately;
lower scores on these two items represent better perceived blood
glucosecontrol.Missingdataateachassessmentwereimputedas
the average of the valid item values.
Weight-related quality of life (IWQOL-Lite)
The impact of weight-related QOL was assessed with the
IWQOL-Lite, a 31-item self-report measure assessing weight-
related QOL in ﬁve domains: physical function, self-esteem,
sexual life, public distress and work [5]. The IWQOL-Lite has
demonstrated robust psychometric properties in obese persons
with and without diabetes [20]. IQWOL-Lite scores (total score
and separate scores for each of the ﬁve domains) range from 0 to
100,with0representingtheworstoutcomeand100representing
the best. Raw scores for each of the IWQOL-Lite scales were
computed only if at least 50% of the items for that scale were
answered, and the total score was computed only if at least 75%
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assessment were imputed as the average of the valid item values.
Statistical analysis
The intent-to-treat population, deﬁned as all randomized
subjects who received at least one injection of study medication
(exenatide), was used. All tests of treatment effects were
conducted at a two-sided signiﬁcance level of 0.05. There was
no adjustment in signiﬁcance levels for multiple comparisons.
The pre-speciﬁed primary analysis of PROs was to compare the
treatment effects between groups at week 30.
ancova [adjusted for baseline DTSQ-s or IWQOL-Lite score,
HbA1c strata (screening HbA1c <9 . 0v s .‡ 9.0%), treatment
groupandsulphonylurea use atscreening(Yesvs.No)]wasused
to estimate least squares (LS) mean group changes from baseline
to week 30. Two-sided 95% conﬁdence intervals (CIs) were
computed for changes at week 30. ancova used last observation
carried forward (LOCF); the last available post-baseline
observation (including Early Termination) was used to impute
missing data for the PRO measures, as long as the subject had
PRO data for at least one post-baseline (including Early
Termination) visit.
LS mean change and the within-group standard deviation of
change were used to calculate standard response mean (SRM)
effect sizes (i.e. measure the magnitude of treatment effect for
each group) [21]. Effect sizes of small, medium and large are
indicatedbycut-offsof0.20,0.50and0.80,respectively[21,22].
PairwiseStudent’st-testsforcorrelatedoutcomeswereusedto
estimate change in DTSQ-s and IWQOL-Lite from week 30 to
week 52 for each treatment group. Change within the group
switchingfromexenatideBIDtoQWprovidesadirecttestofthe
effect of changing exenatide regimens.
Results
Baseline characteristics
TheITTpopulationcomprised295patients(148exenatideQW,
147exenatideBID).Demographicandbaselineclinicalvariables
are summarized in Table 1. Mean age of study participants was
55 years, slightly more than half were male and the majority of
theparticipantswerewhite,withameanbodymassindex(BMI)
of35 kg⁄m
2,ameanHbA 1cof8.3%andmeandiabetesduration
of 6–7 years. On entry to the study, participants were treated
eitherwithdietandexercisealoneorwithoneormoreofavariety
of oral glucose-lowering agents. There were no statistically
signiﬁcant differences between the two treatment groups for any
of these characteristics [13] nor for baseline PRO scores.
Effect of exenatide treatment on diabetes treatment
satisfaction
Atweek30,totalDTSQ-sscoreshadimprovedsigniﬁcantlyfrom
baseline in both treatment arms (P < 0.001), with signiﬁcant
improvement for all speciﬁc items, except for perceived
hypoglycaemia frequency in the exenatide QW arm, and
signiﬁcant improvement for all items, except perceived
hypoglycaemia frequency and treatment convenience in the
exenatideBIDarm.EffectsizesforchangeinDTSQ-stotalscores
at week 30 were 0.84 for exenatide QW compared with 0.64 for
exenatide BID. Statistically signiﬁcant improvements in total
treatment satisfaction for both treatment regimens met the
conventional criterion for clinical meaningfulness [‡ 0.5
standard deviation (sd) units], as assessed by the standardized
responsemean[22].EffectsizesforchangeinDTSQ-sindividual
items from baseline to week 30 ranged from 0.06 to 1.25 in the
exenatide QW group and 0.11 to 0.87 in the exenatide BID
group.
At week 30, between-treatment group differences in DTSQ-s
total scores were not statistically signiﬁcant (P = 0.09), but
treatment satisfaction did improve more in the exenatide QW
arm for perceived hyperglycaemia frequency (P = 0.03) and
willingness to continue current treatment (P = 0.01).
From week 30 to week 52 (Table 3), patients who switched
from exenatide BID to exenatide QW experienced signiﬁcantly
improved total treatment satisfaction (P = 0.037), treatment
Table 1 Baseline demographic and clinical characteristics of subjects
with Type 2 diabetes participating in a 30-week, randomized, multi-centre,
open-label study of exenatide treatment
Characteristic
Exenatide
QW
(n = 148)
Exenatide
BID
(n = 147)
Age (years), mean  sd 55  10 55  10
Gender, n (%)
Male 82 (55) 75 (51)
Female 66 (45) 72 (49)
Race⁄ethnicity, n (%)
White 123 (83) 107 (73)
Black 9 (6) 19 (13)
Hispanic 16 (11) 20 (14)
Asian 0 (0) 1 (1)
Weight (kg), mean  sd 102  19 102  21
BMI (kg⁄m
2), mean  sd 35  53 5  5
HbA1c (%), mean  sd 8.3  1.0 8.3  1.0
Duration of diabetes
(years), mean  sd
7  66  5
Diabetes management
at screening, n (%)
Diet⁄exercise 21 (14) 23 (16)
Metformin only 56 (38) 50 (34)
Sulphonylureas only 6 (4) 10 (7)
Thiazolidinediones only 2 (1) 7 (5)
Metformin + sulphonylureas 43 (29) 39 (27)
Metformin + thiazolidinediones 13 (9) 11 (8)
All metformin* 114 (77) 102 (69)
All sulphonylureas* 55 (37) 54 (37)
All thiazolidinediones* 22 (15) 25 (17)
*Includes speciﬁed agent alone or in combination.
BID, twice daily; BMI, body mass index; HbA1c, glycated
haemoglobin; QW, once weekly; sd, standard deviation.
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satisfaction with continuing treatment (P = 0.048). Patients
who continued with exenatide QW experienced signiﬁcantly
improved satisfaction with treatment convenience (P = 0.006)
and treatment ﬂexibility (P = 0.025) from week 30 to week 52.
All signiﬁcant improvements in treatment satisfaction from
baseline to week 30 remained signiﬁcant in comparisons from
baseline to week 52.
Effectsofexenatidetreatmentonweight-relatedqualityoflife
At week 30 (Table 2), IWQOL-Lite total scores and all separate
domainscoreshadincreasedsigniﬁcantlyinbothtreatmentarms
(allP < 0.001).EffectsizesforchangeinIWQOL-Litetotalscore
at week 30 were 0.96 for the exenatide QW and 0.82 for the
exenatide BID group. Statistically signiﬁcant improvements in
total treatment satisfaction for both treatment regimens met the
conventional criterion for clinical meaningfulness (‡ 0.5 sd
units), as assessed by the standardized response mean [21,22].
There were no statistically signiﬁcant differences in weight-
related QOL between treatment arms.
Patients who switched from exenatide BID to QW at week
30 (Table 3) reported further signiﬁcant improvement for the
physical function (P = 0.04) and public distress (P < 0.001)
domains. Patients who continued on QW improved
signiﬁcantly from week 30 to week 52 for public distress
(P < 0.001). All signiﬁcant improvements in QOL from
baseline to week 30 remained signiﬁcant in comparisons
from baseline to week 52.
Potential mediators⁄moderators of effects on treatment
satisfaction and quality of life
Therewasnosigniﬁcantdifferenceintotaltreatmentsatisfaction
in the 89 subjects who experienced nausea and⁄or vomiting vs.
the190whodidnot(P = 0.97)andtheeffectdidnotdifferacross
treatment arms (P = 0.59). Treatment satisfaction was also
similar for patients who did (n = 61) or did not (n = 218)
experienceaninjectionsitereaction(P = 0.41);theeffectdidnot
differ across treatment arms (P = 0.44).
There was no signiﬁcant difference in overall weight-related
QOL in subjects who did and did not experience nausea
(P = 0.56), a common side effect of exenatide therapy, and the
effect did not differ across treatment arms (P = 0.42). There was
also no signiﬁcant difference in weight-related quality of life in
subjectswhodidanddidnotexperienceaninjectionsitereaction
(P = 0.70); the effect did not differ across treatment arms
(P = 0.49).
Discussion
In this study, treatment satisfaction and weight-related QOL
were signiﬁcantly improved with the addition of exenatide to
treatment with diet, exercise and⁄or oral glucose-lowering
medication. Beneﬁts were substantial and were manifest across
the full range of dimensions studied. Treatment satisfaction
and weight-related QOL improved signiﬁcantly from baseline
to week 30 in both treatment arms, with no signiﬁcant
difference between treatment arms in total treatment
satisfaction or QOL, but a greater improvement in the
exenatide QW arm in perceived hyperglycaemia frequency
and willingness to continue current treatment. All
improvements were sustained from week 30 to week 52
among patients who continued with exenatide QW; moreover,
there were signiﬁcant improvements in treatment convenience
and treatment ﬂexibility. In addition, patients who switched
from exenatide BID to exenatide QW at week 30 reported
signiﬁcantly improved total treatment satisfaction, treatment
convenience, treatment ﬂexibility and satisfaction with
continuing treatment at week 52.
This study is the ﬁrst to assess treatment satisfaction and
quality of life in patients treated with exenatide QW and our
ﬁndings suggest that both exenatide QW and exenatide BID are
associated with statistically signiﬁcant and clinically meaningful
improvements (i.e. moderate or greater effect sizes) in these
important patient-reported outcomes. The fact that
improvements in treatment satisfaction and quality of life were
maintained over 52 weeks suggests that these effects are durable
and the fact that participants continued to prefer exenatide to
their pre-study treatment regimen suggests that patients may be
willing to continue to manage their Type 2 diabetes with
exenatide treatment. Sustained use in the general population of
patients with diabetes could bring many patients the beneﬁts
associated with exenatide treatment in clinical trials, including
improvedbloodglucosecontrolandsigniﬁcantlyreducedweight
[10–14].
We found some evidence that use of exenatide QW was
associated with greater improvements in treatment satisfaction
than use of exenatide BID. At week 30, patients in the
exenatide QW arm were signiﬁcantly more likely than those in
the exenatide BID arm to be willing to continue taking the
study medication and, between weeks 30 and 52, patients who
switched to exenatide QW improved on a number of treatment
satisfaction measures, including total satisfaction and
willingness to continue treatment. This suggests that
acceptance of exenatide QW may be even greater than that
for exenatide BID, perhaps because of ease of use and less
frequent administration regimen of once weekly. Another
possible reason for the greater acceptance of exenatide QW is
the greater improvement in glucose control [13,14]; notably,
reduction in the perceived frequency of hyperglycaemia was
the speciﬁc beneﬁt for which exenatide QW had the largest
advantage over exenatide BID.
The common adverse effects of treatment experienced in
this study (nausea⁄vomiting or injection site reactions), which
were more common in the exenatide BID group [13,14], did
not affect patients’ treatment satisfaction or quality of life.
This suggests that these adverse effects were not severe
enough to affect patients’ perceptions of the study
medications.
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Strengths of the study include the substantial number of
participants and the relatively long duration of the trial. In
addition, the study outcomes, treatment satisfaction and quality
of life were assessed using validated questionnaires likely to be
sensitive to the established clinical effects of the study
medication. The study design allowed us to assess not only the
effects of each formulation of the study medication in patients
who had never taken exenatide, but also the effects of switching
toexenatideQWinpatientswhohadbeentakingexenatideBID.
Finally, we were able to assess the effects of commonly reported
medication side effects on treatment satisfaction and quality
of life.
Study limitations
Study design limitations include the fact that there was no
placebo comparator group that continued with their pre-study
medications to assess placebo effects and there was no
crossover from exenatide QW to exenatide BID to assess
order effects. These features would have required a larger and
longer-term study. A longer-term follow-up of exenatide QW
would have been beneﬁcial, but the design did permit 52 weeks
of patient experience which is the longest term study of
exenatide QW to date; 3.5-year follow-up data on exenatide
BID has already been published [23]. Also, the participation of
ethnic minorities was rather low, limiting the generalizability
of the study ﬁndings to these groups. Finally, it would have
been useful to examine outcomes for psychological well-being
and diabetes distress.
Implications for future research
While the results suggest that exenatide BID and QW are both
viable treatment strategies, it remains to be seen whether the
different medications are preferred by different patient
subgroups. Systematic evaluation of patient differences that
account for alternative preferences should be pursued.
Clinical implications
Exenatide treatment has been associated with important clinical
beneﬁts, including improved glucose control and weight loss
[10,11,13,14]. Patients previously treated with diet and exercise
and⁄ororalmedicationreportedimprovedweight-relatedQOL,
highersatisfaction with the study medication than their previous
therapy and more willingness to continue taking the medication
and recommend it to others. They also reported that the study
medication was more ﬂexible and convenient, despite the fact
that it involved taking injections. Moreover, the recognized side
effects of exenatide treatment—nausea⁄vomiting and injection
site reactions—did not affect treatment satisfaction and quality
of life in this study, suggesting that these effects might not be a
barrier to patients’ accepting treatment with these medications.
Finally, patients switching from exenatide BID to exenatide
QWreportedadditionalimprovementsintreatmentconvenience
and overall treatment satisfaction. Not surprisingly, patients
seemtoprefertakingamedicationonceaweekratherthantwice
a day. This simpler regimen could improve treatment adherence
in real-world clinical settings [24].
In combination with earlier ﬁndings from this study
[13,14], our results indicate it is possible for patients
Table 3 Change ( sd)f r o mw e e k3 0t ow e e k
52 in Diabetes Treatment Satisfaction
Questionnaire—Status version (DTSQ-s) and
Impact of Weight on Quality of Life—Lite
(IWQOL-Lite) among subjects with Type 2
diabetes participating in a randomized, open-
label study ofexenatide treatment (intent-to-treat
population)
Exenatide QW Exenatide BID ﬁ QW
n† Change n† Change
DTSQ
DTSQs total score 119 0.65  3.8 123 1.16  6.1*
Treatment satisfaction—current 119 0.10  0.77 123 0.01  1.2
Perceived frequency high blood sugar 119 )0.04  1.9 123 )0.15  1.8
Perceived frequency low blood sugar 119 )0.18  1.4 123 )0.21  1.4
Treatment convenience 119 0.30  1.2** 123 0.42  1.6**
Treatment ﬂexibility 119 0.24  1.2* 122 0.39  1.7*
Understanding of diabetes 119 0.06  0.94 123 0.04  1.2
Treatment recommend 119 )0.05  0.94 123 0.07  1.1
Treatment satisfaction—continue 119 )0.01  0.93 123 0.24  1.3*
IWQOL-Lite
IWQOL-Lite total score 120 0.36  7.1 127 1.44  8.7
Physical function 121 0.08  9.5 128 2.13  11.5*
Self-esteem 121 0.83  10.9 128 1.12  11.5
Sexual life 118 0.64  17.3 124 0.91  15.2
Public distress 120 6.96  13.2*** 127 5.04  11.2***
Work 119 0.42  9.8 125 1.10  11.2
*P £ 0.05; **P < 0.01; ***P < 0.001.
†Number of subjects with week 30 and week 52 scores.
BID, twice daily; QW, once weekly; sd, standard deviation.
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exenatide therapy with potential beneﬁts in both clinical
efﬁcacy and patient-reported outcomes directly related to
treatment adherence.
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